Torrance Memorial Physician Network / Cancer Care

Summary

Torrance Memorial Physician Network / Cancer Care is a medical facility located in Torrance, California. This center is recognized for care of Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast cancer, Pancreatic Cancer and other specialties. Torrance Memorial Physician Network / Cancer Care is involved with conducting 51 clinical trials across 108 conditions. There are 15 research doctors associated with this hospital, such as Andrew Hendifar, MD, Jun Gong, MD, David Chan, M.D., and Yuan Yuan, MD PhD.

Top PIs

Clinical Trials running at Torrance Memorial Physician Network / Cancer Care

Breast Cancer

Lung Cancer

Skin Cancer

Breast cancer

Ovarian Cancer

Non-Small Cell Lung Cancer

Pancreatic Neuroendocrine Tumors

Prostate Cancer

Eyelid Cancer

Kidney Cancer

Radiation and HER2-Targeted Therapy

for Breast Cancer

This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.

Recruiting

2 awards

Phase 3

15 criteria

Imlunestrant

for Early Breast Cancer

This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.

Recruiting

2 awards

Phase 3

6 criteria

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

Recruiting

2 awards

Phase 3

40 criteria